KardiaMobile 6L can be used to measure QT duration in COVID-19 patients - Cardiac Rhythm News

KardiaMobile 6L, which it describes in a press release as the world’s only six lead personal ECG.

Kardiamobile 6L allowed to detect QT prolongation in COVID-19 patients

RApid Throughput Screening for Asymptomatic COVID-19 Infection With an Electrocardiogram: A Prospective Observational Study - Mayo Clinic Proceedings: Digital Health

Feasibility of using KardiaMobile-L6 for QT interval monitoring during the early phase of the COVID-19 pandemic in critical care patients

Rhythm strips used for QTc measurement. These rhythm strips were

Artificial Intelligence–Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement - Lenihan - 2020 - CA: A Cancer Journal for Clinicians - Wiley Online Library

AliveCor and Thomas Jefferson University Hospital Partner to Evaluate KardiaMobile 6L for QT Prolongation Screening in Patients Treated for Opioid Use Disorder

Feasibility of using KardiaMobile-L6 for QT interval monitoring during the early phase of the COVID-19 pandemic in critical care patients

AliveCor gains US FDA clearance for KardiaMobile 6L to calculate patients' QTc interval - Medical Device News by Guided Solutions

Accuracy of mobile 6-lead electrocardiogram device for assessment of QT interval: a prospective validation study